Cytosorbents Pushes US Approval for Blood Thinner Reversal Device

Ticker: CTSO · Form: 10-K · Filed: Mar 30, 2026 · CIK: 0001175151

Sentiment: mixed

Topics: Medical Devices, Biotechnology, FDA Approval, Cardiac Surgery, Blood Purification, Critical Care, Antithrombotic Reversal

TL;DR

**CTSO is a speculative buy, betting on DrugSorb-ATR's FDA approval to unlock a massive market in cardiac surgery.**

AI Summary

Cytosorbents Corp (CTSO) reported a focus on its proprietary blood purification technologies, particularly CytoSorb and the investigational DrugSorb-ATR. CytoSorb, approved in the EU and distributed in over 70 countries with more than 300,000 devices used, targets severe inflammation and toxin removal in critical illnesses. It received FDA EUA in April 2020 for critically ill COVID-19 patients but is not yet fully approved in the U.S. The company is actively pursuing U.S. FDA and Health Canada approval for DrugSorb-ATR, an antithrombotic removal system, which has received two FDA Breakthrough Device Designations for ticagrelor, apixaban, and rivaroxaban removal. The initial De Novo application for ticagrelor removal in CABG patients was submitted in September 2024 and accepted for substantive review in October 2024. The estimated total addressable market for DrugSorb-ATR is $300 million initially, potentially growing to over $1 billion. The company also commercializes ECOS-300CY in the EU for ex vivo organ perfusion and VetResQ for animal critical care.

Why It Matters

Cytosorbents' DrugSorb-ATR, if approved, could significantly impact cardiac surgery by allowing patients on blood thinners like Brilinta to undergo urgent procedures without dangerous delays, reducing severe bleeding risks. This innovation could improve patient outcomes, streamline hospital operations by reducing ICU recovery times and enhancing surgical throughput, and offer a competitive edge in the medical device market for blood purification. For investors, successful U.S. and Canadian commercialization of DrugSorb-ATR, with an initial addressable market of $300 million, represents a substantial growth opportunity in a critical unmet medical need.

Risk Assessment

Risk Level: high — The company's lead product, CytoSorb, is not yet approved in the United States, and the investigational DrugSorb-ATR is still awaiting U.S. FDA and Health Canada marketing approval. The success of DrugSorb-ATR is critical, with the company 'actively pursuing regulatory approval' and 'expecting to rapidly commercialize' upon approval, indicating significant reliance on future regulatory decisions and market acceptance for its projected $300 million to $1 billion addressable market.

Analyst Insight

Investors should closely monitor the U.S. FDA's review process for DrugSorb-ATR, particularly the De Novo application submitted in September 2024. A positive approval could be a significant catalyst, but the stock carries high regulatory risk until then. Consider a small, speculative position if you believe in the technology's potential and are comfortable with the inherent regulatory uncertainties.

Financial Highlights

debt To Equity
X.X
revenue
$60.6 million
operating Margin
X%
total Assets
$X
total Debt
$X
net Income
$X
eps
$X
gross Margin
X%
cash Position
$X
revenue Growth
+X%

Key Numbers

Key Players & Entities

FAQ

What is CytoSorbents Corporation's primary business focus?

CytoSorbents Corporation (CTSO) focuses on blood purification technologies for life-threatening conditions in intensive care and cardiac surgery. Their lead product, CytoSorb, is approved in the EU and used in over 70 countries for inflammation and toxin removal, while DrugSorb-ATR is an investigational device for blood thinner reversal in surgery.

What is the current regulatory status of CytoSorb in the United States?

CytoSorb received U.S. FDA Emergency Use Authorization (EUA) in April 2020 for adult critically ill COVID-19 patients with respiratory failure. However, it is not yet fully cleared or approved for general use in the United States.

What is DrugSorb-ATR and its potential market size for Cytosorbents?

DrugSorb-ATR is an investigational device designed to remove antithrombotic drugs during cardiothoracic surgery, reducing bleeding risk. Cytosorbents estimates its initial total addressable market at $300 million, with potential to grow to over $1 billion by expanding indications beyond cardiac surgery.

When did Cytosorbents submit its De Novo application for DrugSorb-ATR to the FDA?

Cytosorbents submitted its initial De Novo medical device application for DrugSorb-ATR to the U.S. FDA in September 2024, requesting marketing approval for ticagrelor removal in CABG patients. The application was accepted for substantive review in October 2024.

What are the benefits of DrugSorb-ATR for patients and hospitals?

For patients, DrugSorb-ATR aims to enable critical CABG surgery without significant delay and reduce severe bleeding risk. For hospitals, it could lead to decreased washout times, fewer expensive ICU recoveries, faster throughput of cardiac surgeries, and improved quality ratings by reducing adverse events.

What is the significance of FDA Breakthrough Device Designations for DrugSorb-ATR?

DrugSorb-ATR received two FDA Breakthrough Device Designations: one for ticagrelor removal (2020) and another for apixaban and rivaroxaban removal (2021). These designations indicate the FDA's recognition of the device's potential to provide more effective treatment for life-threatening or irreversibly debilitating conditions.

How many patients are targeted by DrugSorb-ATR for ticagrelor removal in the U.S. and Canada?

DrugSorb-ATR initially targets approximately 60,000 patients annually in the U.S. and Canada who are on the anti-thrombotic drug Brilinta (ticagrelor) and require urgent cardiovascular surgery.

What other products does Cytosorbents commercialize besides CytoSorb and DrugSorb-ATR?

Beyond CytoSorb and DrugSorb-ATR, Cytosorbents commercializes ECOS-300CY in the EU for ex vivo organ perfusion in transplant, and VetResQ for emergency and critical care in animals, primarily in the U.S. They also commercialize the PuriFi hemoperfusion pump internationally.

What is Cytosorbents' strategy for reimbursement for DrugSorb-ATR in the U.S.?

Given DrugSorb-ATR's FDA Breakthrough Device status and the target population falling under CMS, Cytosorbents expects to pursue additional reimbursement and coverage options through the New Technology Add on Payment (NTAP) and Transitional Coverage for Emerging Technologies (TCET) programs.

What is the aggregate market value of Cytosorbents' common stock held by non-affiliates?

As of June 30, 2025, the aggregate market value of Cytosorbents' common stock held by non-affiliates was approximately $60.6 million, based on the closing price reported on the Nasdaq Capital Market Exchange.

Risk Factors

Industry Context

The critical care and extracorporeal blood purification market is characterized by a focus on improving patient outcomes in life-threatening conditions. Companies are developing advanced technologies to remove toxins, inflammatory mediators, and specific drugs from the bloodstream. Key trends include the increasing use of blood purification in sepsis, organ failure, and post-operative complications, as well as the development of targeted therapies for specific drug removal.

Regulatory Implications

The company's success is highly dependent on navigating complex regulatory pathways, particularly with the FDA in the United States. Obtaining approval for DrugSorb-ATR is a critical step, and any delays or setbacks in the De Novo review process could significantly impact its market entry and revenue generation potential.

What Investors Should Do

  1. Monitor FDA review progress for DrugSorb-ATR.
  2. Assess international sales performance of CytoSorb.
  3. Evaluate the company's cash burn rate and future financing needs.
  4. Track clinical evidence and adoption rates for CytoSorb in new indications.

Key Dates

Glossary

CytoSorb
The company's proprietary blood purification cartridge designed to remove inflammatory mediators and toxins from blood. (The company's lead product, with significant international distribution and a focus for U.S. regulatory efforts.)
DrugSorb-ATR
An investigational antithrombotic removal system developed by the company to reduce bleeding risk in patients on blood thinners undergoing surgery. (A key product in development with FDA Breakthrough Device Designations, representing significant future revenue potential.)
CE mark
A certification that a product meets European Union (EU) standards for health, safety, and environmental protection. (Indicates CytoSorb's approval and market access within the European Union.)
FDA EUA
Food and Drug Administration Emergency Use Authorization, allowing unapproved medical products to be used in emergencies. (Granted for CytoSorb during the COVID-19 pandemic, showing potential but not full U.S. market approval.)
De Novo application
A regulatory pathway in the U.S. for novel medical devices that are low-to-moderate risk and do not have a predicate device. (The pathway being used for DrugSorb-ATR's U.S. approval, indicating its novelty and the regulatory process involved.)
Breakthrough Device Designation
A designation by the FDA for devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. (Highlights the FDA's recognition of DrugSorb-ATR's potential clinical benefit and may expedite the review process.)
Cytokine release syndrome
A severe systemic inflammatory response that can occur in patients treated with certain therapies, characterized by the rapid release of cytokines. (One of the critical illnesses targeted by CytoSorb for removal of inflammatory agents.)
Antithrombotic
A drug that prevents the formation of blood clots. (Describes the class of drugs that DrugSorb-ATR is designed to remove, addressing a specific clinical need.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available from the provided text. The 10-K filing details the current year's financial condition and operations, but comparative year-over-year data requires access to the prior year's filing.

Filing Stats: 4,419 words · 18 min read · ~15 pages · Grade level 13.5 · Accepted 2026-03-30 07:04:46

Key Financial Figures

Filing Documents

Business

Item 1. Business. 1

Risk Factors

Item 1A. Risk Factors. 18

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments. 33

Cybersecurity

Item 1C. Cybersecurity 33

Properties

Item 2. Properties. 34

Legal Proceedings

Item 3. Legal Proceedings. 34

Mine Safety Disclosures

Item 4. Mine Safety Disclosures. 34 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 35

Reserved

Item 6. Reserved 35

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. 35

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 43

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data. 43

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure. 43

Controls and Procedures

Item 9A. Controls and Procedures. 44

Other Information

Item 9B. Other Information. 46

Disclosure Regarding Foreign Jurisdictions that Prevent Inspection

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspection. 46 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance. 47

Executive Compensation

Item 11. Executive Compensation. 47

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 47

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence. 47

Principal Accounting Fees and Services

Item 14. Principal Accounting Fees and Services. 47 Part IV

Exhibits, Financial Statement Schedules

Item 15. Exhibits, Financial Statement Schedules. 48

Form 10-K Summary

Item 16. Form 10-K Summary 53 i Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K, or this Report, contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as "anticipate," "believe," "estimate," "intend," "could," "should," "would," "may," "seek," "plan," "might," "will," "expect," "predict," "project," "forecast," "potential," "continue," negatives thereof or similar expressions. These forward-looking statements are found at various places throughout this Report and include information concerning possible or assumed future results of our operations; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future cash needs, business plans and future financial results, and any other statements that are not historical facts. Unless otherwise indicated, the terms "CytoSorbents," "Company," "we," "us" and "our" refer to CytoSorbents Corporation. From time to time, forward-looking statements also are included in our other periodic reports on Forms 10-Q and 8-K, in our press releases, in our presentations, on our website and in other materials released to the public. Any or all of the forward-looking statements included in this Report and in any other reports or public statements made by us are not guarantees of future performance and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and cou

Business

Item 1. Business. Overview We are a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses include, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorbents' lead product, CytoSorb, is approved in the European Union and distributed in more than 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical condi

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing